3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Melanoma
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Somatostatinoma
1
Solitary Fibrous Tumor, Pleural
1
Primary Myelofibrosis
1
Pheochromocytoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Metastatic Non-hematologic Malignancies
1
Meningioma
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Sunitinib
26
Everolimus
20
Bevacizumab
19
aldesleukin
18
Sorafenib
16
Nivolumab
16
Interleukin-2
14
pembrolizumab
13
Peripheral Blood Stem Cell Transplantation
13
fludarabine phosphate
12
Radiotherapy
12
Interferon-alpha
12
Cyclophosphamide
12
Radiosurgery
11
Filgrastim
11
Blood Specimen Collection
11
Ipilimumab
10
Gemcitabine
10
Axitinib
9
Surveys and Questionnaires
7
Gene Expression Profiling
7
Cryosurgery
7
temsirolimus
6
pazopanib
6
Surgical Procedures, Operative
6
durvalumab
5
cabozantinib
5
atezolizumab
5
Mycophenolic Acid
5
Immunohistochemistry
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Kidney Neoplasms
×
vatalanib
×
Clear all
NCT00303732
2016-03-03
PTK/RAD
Duke University
Phase 1
Completed
37 enrolled